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Over the past two years, evidence has emerged that the currently available thiazolidinediones (TZDs), rosiglitazone, and
pioglitazone have negative skeletal consequences, at least in women, which are clinically important. Increased fracture risk in
women, but not men, was reported for both TZDs, based on analyses of adverse event reports from clinical trials. In short-term
clinical trials in women, both TZDs caused more rapid bone loss. In these trials, changes in bone turnover markers suggest a
patternofreducedboneformationwithoutachangeinresorption.Althoughlimited,theseresultssupportthehypothesisbasedon
rodent and in vitro models that reduced bone formation resulting from activation of peroxisome proliferator-activated receptor-γ
(PPARγ) is a central mechanism for TZDs’ eﬀect on bone. Research is needed to better understand the mechanisms of bone loss
with TZDs, to identify factors that inﬂuence susceptibility to TZD-induced osteoporosis, and to test treatments for its prevention.
Copyright © 2008 Ann V. Schwartz. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Recent reports have substantially advanced our knowledge of
the clinical eﬀects of TZDs on skeletal health. In early 2006,
research into the skeletal eﬀects in humans of rosiglitazone
and pioglitazone, the currently prescribed TZDs, was limited
to observational studies [1]. Although a body of evidence
had developed from rodent and in vitro studies that these
two TZDs cause bone loss, it was not known if these
compounds had a similar eﬀect in humans. Since then,
rosiglitazone and piogltiazone were each linked to increased
fracture risk among diabetic women, based on adverse
event reports in clinical trials. And, in women, short-term
clinical trials demonstrated substantial bone loss with both
TZDs. Pioglitazone and rosiglitazone are widely used to
treat diabetes, and better knowledge of their skeletal eﬀects
is crucial to guide clinical decisions. At the same time,
b e c a u s eT Z D sa r el i g a n d so fP P A R γ, a better understanding
of their skeletal eﬀects will help to clarify the role of
PPARγ in bone metabolism and potentially shed light on the
mechanisms of age-related bone loss. This review considers
the recent clinical evidence regarding TZDs and skeletal
health and discusses outstanding issues that warrant further
research.
2. ROSIGLITAZONE AND FRACTURE RISK
Evidence that RSG increases fracture risk emerged with
the results of the ADOPT trial published in 2006 [2]. A
postproof note in the main report from the trial indicated
increased fracture risk in women, but not men, enrolled
in the trial. Since then, the fracture results have been
published separately and in more detail [3]. ADOPT was
designed to assess time to monotherapy failure for RSG
compared to metformin and to a sulfonylurea, glyburide.
Thetrialhadthreearms,correspondingtothethreediﬀerent
treatments, and enrolled a total of 2511 men and 1840
women who were followed for a median of 4.0 years.
The average age was 57 years. By self-report, 77% of
women were postmenopausal. Participants were recently
diagnosed with diabetes (<3 years), were drug na¨ ıve for
hypoglycemic medications, and had an averageA1C of about
7.4%.
Fractures, identiﬁed through adverse event reports,
were speciﬁcally reviewed after the conclusion of the trial.
Based on time to ﬁrst fracture, the investigators found
an increased risk among women in the RSG arm of 1.81
(95% CI: 1.17, 2.80) compared to metformin, and 2.13
(1.30, 3.51) compared to glyburide. The risk for men was2 PPAR Research
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Figure 1: Kaplan-Meier estimates of the cumulative incidence of
fractures at ﬁve years in women enrolled in ADOPT [3]. Bars
represent 95% conﬁdence intervals.
not increased compared with either metformin (RH 1.18;
95% CI: 0.72, 1.96) or glyburide (RH 1.08: 95% CI: 0.65,
1.79).
In women, risk was increased for both upper and lower
limb fractures. Rate ratios calculated from fracture rates
reported for ADOPT showed the largest increases in relative
risk for foot (RR = 3.3), hand (RR = 2.6), and proximal
humerus (RR > 8) fractures (see Table 1). There was no
increased risk identiﬁed for clinical spine or hip fractures,
but the numbers of these fractures, 3 clinical spine and 4
hip fractures among all women, were too small to draw ﬁrm
conclusions. The small number of hip and spine fractures
in the ADOPT population (average age 57 years) is not
surprising since the rate of these fractures tends to be
relatively low until after age 65.
For women, an examination of the survival curves from
the ADOPT trial (see Figure 1) suggests that the increased
risk of fracture with RSG is evident after about one year of
treatment.Inseparatetrials,discussedbelow,bonelosscould
be identiﬁed among women treated with RSG after only
a few months of treatment. However, the ADOPT results
suggest that bone loss with RSG does not make a noticeable
diﬀerence in fracture risk until after about 12 months of
treatment.
Self-reported menopausal status and baseline use of
estrogen-containing hormones were available for women
enrolled in ADOPT. As expected, premenopausal women
had a lower rate of fracture than postmenopausal women,
but both groups had an approximate doubling of fracture
risk with RSG treatment. Menopausal status did not appear
to substantially modify the eﬀects of RSG on fracture. About
20% of women reported use of an estrogen-containing
hormone at baseline. The eﬀect of RSG on fracture risk did
not appear to diﬀer between those who did or did not report
estrogen use.
It is possible, though not established, that poor glycemic
control increases fracture risk [6]. However, this would
not explain the ADOPT results as those in the RSG arm
maintained glycemic control on monotherapy longer than
those in the metformin or glyburide arms.
3. PIOGLITAZONE AND FRACTURE RISK
With the published report of increased fracture risk in
the RSG arm of ADOPT, Takeda Pharmaceuticals, IL, USA
the manufacturer of pioglitazone, reviewed their clinical
trial databases and, in a letter to health care providers in
2007, reported an increased fracture risk with pioglitazone
treatment in women, but not men [7]. The databases
included 24000 years of followup for over 8100 patients
treated with pioglitazone and over 7400 patients in the
comparison group. In these trials, the maximum duration of
pioglitazone use was only 3.5 years. The magnitude of the
increased risk reported for all clinical fractures was similar
to the ADOPT results with a fracture rate of 1.9 per 100
person years in those using pioglitazone compared with a
rate of 1.1 per 100 person years in those using placebo or
an active comparator drug. The relative risk for men was not
reportedbutwasstatedtobenotstatisticallysigniﬁcant.Data
on speciﬁc fracture sites was not provided although the letter
stated that most of the fractures occurred in the distal upper
limb or distal lower limb.
4. TZDs AND BONE LOSS
In 2007, Grey et al. reported the results of a 14-week
randomized clinical trial comparing RSG (8mg/day) with
p l a c e b oi n5 0p o s t m e n o p a u s a lw o m e n ,a v e r a g ea g e6 7y e a r s ,
who did not have diabetes or osteoporosis [8]. The trial
found modest reductions in two markers of bone formation.
Procollagen type-I N-terminal propeptide was reduced by
13% (P = .004) and osteocalcin by 10% (P = .04) in
the RSG arm compared with placebo. In contrast, the bone
resorption marker, serum β-C-terminal telopeptide (S-CTX)
of type I collagen, was stable in the RSG arm and did
not diﬀer signiﬁcantly from placebo (P = .9). Substantial
bone loss was reported at the total hip with RSG treatment.
Women in the RSG group lost bone density (BMD) more
rapidly at the total hip (−1.9% RSG versus −0.2% placebo,
P = .003).Forthetotalspine,bonelosswasmorerapidinthe
R S Ga r mb u tt h ed i ﬀerence was not statistically signiﬁcant
(−1.2% RSG versus −0.2% placebo, P = .13).
In a randomized, controlled, but unblinded trial, a lower
dose of RSG(4mg/day) for12 weeks wascomparedwith diet
treatmentaloneinobesepostmenopausalwomenwithnewly
diagnosed diabetes [9]. Bone-speciﬁc alkaline phosphatase,Ann V. Schwartz 3
Table 1: Fracture rates comparing rosiglitazone with metformin or glyburide in ADOPT study. Table adapted from a Letter to Health Care
Providers issued by GSK [4].
Rosiglitazone Metformin or glyburide Relative rate (95% CI)
Women
Total followup (P-Y) 2187.20 3578.80
Fracture site N Rate/100PY N Rate/100PY RR (95% CI)
Lower limb∗ 36 1.65 26 0.73 2.27 (1.33, 3.91)
Hip 2 0.09 2 0.06 1.64 (0.12, 22.57)
Foot 22 1.01 11 0.31 3.27 (1.52, 7.47)
Upper limb† 22 1.01 19 0.53 1.89 (0.98, 3.70)
Hand 8 0.37 5 0.14 2.62 (0.76, 10.17)
Humerus 5 0.23 0 0.00 ‡ (1.50,‡)
Spine 1 0.05 2 0.06 0.82 (0.01, 15.72)
Other 5 0.23 8 0.22 1.02 (0.26, 3.55)
All fractures 64 2.93 55 1.54 1.90 (1.31, 2.78)
Men
Total followup (P-Y) 2766.70 5570.40
N Rate/100PY N Rate/100PY RR (95% CI)
Total participants with any fracture 32 1.16 57 1.02 1.13 (0.71, 1.77)
∗Hip, foot, ankle, femur, ﬁbula, lower limb (general), patella, tibia.
†Hand, humerus, clavicle, forearm, radius, upper limb (general), wrist.
‡Cannot estimate. No events in the comparison group.
Reprinted with permission from [5]
a bone formation marker, was decreased in the RSG arm
(−21.5%) compared with diet only (−4.1%) (P<. 05).
Osteocalcin was decreased similarly in both arms (RSG
−20%; diet only −17.6%) while urine deoxypyridinoline
(DPD), a resorption marker, was not increased in the RSG
arm (3%) compared with the diet only arm (17%).
The short-term eﬀects of pioglitazone (30mg/day) on
bone density and markers have been tested in a 16-week ran-
domized placebo-controlled trial among 30 premenopausal
women with polycystic ovary syndrome (PCOS) [10]. BMD
was reduced compared with placebo at the lumbar spine
(−1.14% versus 0.00%), total hip (−0.18% versus 1.35%),
and femoral neck (−1.45% versus 0.87%) (all P<. 05). The
magnitude of loss in the PIO group at the spine and femoral
neck is similar to BMD losses reported with RSG use over 14
weeks in postmenopausal women [8]. Alkaline phosphatase,
a marker of bone formation, was decreased in the PIO
groupcomparedtoplacebobutosteocalcinwasnot.Changes
in the marker of bone resorption, S-CTX, were also not
signiﬁcantly diﬀerent across treatment groups. The treated
group experienced a signiﬁcant decrease in fasting insulin
comparedtoplacebo.Sinceinsulinmaybeanabolicforbone,
this may have contributed to the bone loss observed with
PIO although the authors reported that the changes in BMD
and the changes in insulin were not signiﬁcantly correlated.
Estradiolandtestosteronelevelswerenotsigniﬁcantlyaltered
in the PIO group.
Two observational studies have reported results for TZDs
and changes in BMD or markers. The ﬁrst clinical study
to report increased bone loss with TZD use, combining
troglitazone, rosiglitazone, and pioglitazone, was based on
the Health, Aging, and Body Composition longitudinal
observationalstudyofolderadults[11].Thecohortincluded
666 diabetic participants with an average age of 73 years.
Of these, 69 participants reported any TZD use during
four years of followup. Increased bone loss was found in
diabetic women but not men. After controlling for potential
confounders, the additional bone loss attributed to TZD
use in women was −1.23% (95% CI: −2.06%, −0.40%)
per year at the lumbar spine, −0.61% (−1.02%, −0.21%)
per year for whole body, and −0.49% (−1.04%, 0.07%)
for total hip. These estimates of increased bone loss are
substantially lower than those reported by Grey et al. [8]
for the trial of RSG use and by Glintborg et al. [10]f o r
the trial of PIO use. The additional bone loss of 1.5–1.7%
at the total hip over 14–16 weeks in these two trials, if
sustained, would result in additional bone loss of 5-6%
annually. While the observational study by Schwartz et al.
may have underestimated the degree of bone loss associated
with TZD use, it seems unlikely that bone loss of 6% per year
is occurring with TZD use. Instead, there may be an initial
period of more rapid bone loss, followed by continued loss
a tal o w e rr a t e ,s i m i l a rt ot h ee ﬀect of glucocorticoids [12].
Although Schwartz et al. reported no increased bone
loss with TZD use in diabetic men, Yaturu et al., in an
observational study of 160 older diabetic men (average age
68 years), did report that RSG use (N = 32) was associated
with increased bone loss of −1.05% per year at the total hip,
−1.02% at the femoral neck, and −1.24% at the spine (all
P<. 03) [13]. However, the study did not have suﬃcient
powertocontrolforpotentialconfounderssuchasA1Clevel,
use of other medications, or diabetic complications.4 PPAR Research
4.1. Rodentandinvitromodels
Results of rodent and in vitro models provided the ﬁrst
evidence that RSG and PIO cause bone loss. RSG has
been more extensively studied in these models but both
compounds are associated with bone loss in rodents [14, 15].
These ﬁndings have been reviewed previously [16, 17]a n d
will not be discussed in depth here. However, a few points
are worth noting as particularly relevant to future research in
humans. In general, these models indicate a negative eﬀect
on osteoblast diﬀerentiation and activity with a decrease
in bone formation. However, in a few reports, TZDs were
associated with increased resorption. Notably, this occurred
in ovariectomized rats [18] and in aged mice [19]. Sottile
et al. reported that ovariectomized rats experienced bone
loss with RSG, but intact female rats did not, and that the
bone loss was characterized by increased resorption [18].
This suggests an interaction between RSG and estrogen
levels that needs to be assessed in human studies. The
results from Lazarenko et al. comparing the eﬀects of RSG
in young, adult, and aged mice suggest that the mechanism
of action may be diﬀerent in the aged mice [19]. In young
a n da d u l tm i c e ,b o n el o s sw i t hR S Gt r e a t m e n tw a sd r i v e n
by reduced formation while in older mice RSG treatment
resulted in increased resorption. These results need to be
explored in human studies as they would suggest diﬀerent
approaches to treatment for the prevention of TZD-induced
osteoporosis.
5. FUTURE DIRECTIONS FOR CLINICAL RESEARCH
Substantial evidence has now emerged that RSG and PIO
have clinically important negative skeletal eﬀects. Increased
fracture risk in women, but not men, has been reported for
both RSG and PIO. Although this increased fracture risk
was identiﬁed in the context of clinical trials, the fractures
were identiﬁed through adverse event reports and were not a
planned outcome of the trials. It is possible for adverse event
results in a clinical trial to give a signal that is statistically
signiﬁcant due to chance rather than to an actual eﬀect of
the intervention. However, the fracture eﬀect is consistent
with two clinical trials demonstrating bone loss with RSG
and PIO. And, the increased fracture risk and bone loss are
consistent with the results of rodent and in vitro models.
The combination of these studies provides a compelling
argumentthat,inwomen,thetwocurrentlyprescribedTZDs
cause higher fracture risk due to bone loss.
Given this growing evidence of increased fracture risk
and bone loss with TZD use, further exploration of the
skeletal eﬀects of TZDs is crucial to inform eﬀorts to prevent
TZD-induced osteoporosis and, more generally, to delineate
the role of PPARγ in bone metabolism. Some of the key
questions for clinical research are identiﬁed and discussed
below.
5.1. Whatgroupsareathigherrisk?
To inform clinical decisions and to better understand the
mechanismofTZDseﬀectsontheskeleton,itisimportantto
ascertain if there are groups that are particularly vulnerable,
or groups that are not susceptible, to increased fracture risk
with TZD use. So far, the negative skeletal eﬀects seem to
be more important for women than for men, but results
are not conclusive. Among women, menopausal status does
not appear to modify the eﬀect of RSG on the skeleton. The
ADOPT results indicate that increased fracture risk extends
to those who are premenopausal as well as postmenopausal.
Both premenopausal [10] and postmenopausal [8]w o m e n
have been shown to lose bone with TZD treatment.
A possible explanation for the lack of eﬀect on the
skeleton in men is the higher estrogen levels found in
older men compared with older women. In a rat model,
ovariectomized, but not intact, females had bone loss with
RSG treatment, suggesting a protective eﬀect from higher
estrogen levels [18]. However, clinical results to date indicate
that TZDs cause increased bone loss and fracture risk in pre-
as well as postmenopausal women. Further research with
measurements of endogenous estrogen levels could clarify
whether there is an interaction between estrogen levels and
TZD use.
5.2. Whathappenstobonedensityandturnover
after3-4monthsoftreatment?
The randomized trials with RSG and PIO have reported on
treatment for 14–16 weeks. In both trials, the additional
bone loss in the treated group was substantial, equivalent
to a loss of 5-6% over a year, but it seems unlikely that this
rate of loss is being sustained over longer treatment periods.
Observational studies suggest increased loss of about 0.5–1%
each year. Steroid treatment appears to cause initial rapid
bone loss followed by continued loss but at a lower rate; the
TZDs may present a similar pattern [12]. However, trials of
longer duration are needed to assess the degree of loss over
several years.
5.3. Effectonresorptionaswellasformation?
One of the key questions regarding the mechanism of action
of the TZDs is whether bone resorption and formation, or
only one, are aﬀected. The clinical evidence to date, based
on bone turnover markers, points to a reduction in bone
formation without a change in bone resorption. However,
these results are based on only three studies that included
bone marker results [8–10]. Rodent models have generally
shown reduced bone formation but, in aged mice and in
ovariectomized rats, bone resorption is increased. Whether
bone resorption is similarly increased with older age or with
very low endogenous estrogen levels in human studies has
not been fully explored.
5.4. Doeffectsoncorticalandtrabecularbonediffer?
The increased fracture risk observed in the bones of the
extremities, that have a relatively high proportion of cortical
bone, suggests a negative impact on cortical bone. This pat-
ternisdistinctfromglucocorticoidswhichhaveaparticularly
strong eﬀect on trabecular bone and the risk of vertebralAnn V. Schwartz 5
fracture [12]. Studies using imaging techniques that can
separate these two compartments, such as high resolution
computed tomography, could clarify whether the eﬀects of
TZDs diﬀer for cortical and trabecular bones.
5.5. Marrowadiposity
In most reports from rodent models, increased marrow
adiposity accompanies bone loss with RSG treatment. Fur-
ther investigation of this phenomenon has suggested that
activation of PPARγ with RSG increases lineage allocation of
stem cells towards adipocytes at the expense of osteoblasts
in the marrow. To date, human studies have not measured
bone marrow adiposity. Knowledge of the eﬀect of TZDs
on bone marrow fat would increase our understanding
of the mechanisms underlying bone loss and fracture risk
in humans with TZD use. In addition, an increase in
bone marrow fat may cause an artiﬁcial decrease in BMD
measuredbyDXA[20].Ifmarrowfatis increased,thedegree
of bone loss with TZD use may be overestimated by DXA
measurements.
5.6. Effectivetreatmentfor
TZD-inducedosteoporosis
Therearenostudiestodateontreatmentsthatmightprevent
TZD-induced bone loss. Although the bisphosphonates
mainly target bone resorption, the general reduction in
bone turnover may be eﬃcacious in preventing bone loss
with TZD treatment. The bisphosphonates are successfully
used for prevention of osteoporosis with corticosteroid
treatment, also characterized by reduced bone formation
[21]. However, TZDs have speciﬁc eﬀects on bone, and
bisphosphonate use should be explicitly tested to determine
eﬃcacy in this situation. Treatments that increase bone
formation, currently limited to parathyroid hormone (PTH)
and strontium ralenate, could theoretically prevent TZD-
induced bone loss. PTH has been shown to prevent bone loss
with glucocorticoid therapy [22], but neither treatment has
been tested in relation to TZDs.
6. CONCLUSION
Research over the past two years has provided new clinical
evidencethatthecurrentlyprescribedTZDsincreasefracture
risk and bone loss, at least in women. Combined with the
ﬁndings from rodent and in vitro models, these clinical
results suggest that activation of PPARγ can play a role in
bone loss. With the widespread use of TZDs as a diabetes
treatment, further research is needed to delineate the groups
that are most susceptible to TZD-induced osteoporosis, to
determine the rate of bone loss with TZD treatment beyond
16 weeks, to assess the eﬀects of TZDs on marrow adiposity,
cortical and trabecular bones, and to identify treatments
to prevent TZD-induced fracture risk. Addressing these
questions will advance our ability to prevent TZD-induced
osteoporosis and will provide a better understanding of the
role of PPARγ activation in bone metabolism.
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